Table 4.
Influence of interfering chemotherapeutic drug (CTD) on affecting antiepileptic drug (AED) activity
| AED | CTD | CTD/dose | Involved Mechanism | No. of Pateints | Change in AED Activity | Factor of Change | Reference |
|---|---|---|---|---|---|---|---|
| Phenytoin Carbamazepine |
Cisplatin | 20 mg/m2 | Protein displacement/ diminished absorption |
1 | Cl ↑ | 2.29 | Neef, 198848 Grossman, 198949 Dofferhof, 199050 |
| Phenytoin | CCNU Cisplatin |
40 mg/m2 40 mg/m2 |
17 | Dose ↑ | 1,39 | ||
| Phenytoin | Carboplatin | 400 mg/m2 | 1 | Dose ↑ | 1.21 | ||
| Phenytoin | 5-Fluorouracil Capecitabine Doxifluridine |
370–425 mg/m2 800 mg/d |
2C9 inhibition | 2 1 1 |
Dose ↓ Dose ↓ Plasma level ↑ |
0.53–0.72 0.46 4 |
Brickell, 200351 Konishi, 200262 Privitera, 201152 |
| Phenytoin | Tamoxifen | 3A, 2C19, 2D6 | 1 | Dose ↑ | 1.16 | Rabinowicz 199553 | |
| Valproic acid | Cisplatin | 30 mg/day (with BEP regimen) | Protein displacement/ diminished absorption |
Plasma level ↓ | 0.5 | Neef, 198848 Ikeda, 200528 |
|
| Valproic acid | Methotrexate | 1 g/m2 | 1 | Plasma level ↓ | 0.25 | Schroder, 199454 | |
| Phenytoine | Vinblastine | 10 mg | Diminished Absorption |
1 | Plasma level ↓ | 0.59 | Bollini, 198326 |